
Please try another search
(Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax (NASDAQ:NVAX) Inc's COVID-19 vaccine for adolescents aged 12 through 17.
The recommendation follows the U.S. Food and Drug Administration's authorization for the vaccine for the age group last week.
The protein-based vaccine received emergency use authorization in July for use among adults in the United States, with health officials hoping it would drive uptake among those skeptical of messenger RNA shots from Moderna (NASDAQ:MRNA) Inc and Pfizer Inc. (NYSE:PFE)
However, Novavax earlier this month halved its full-year revenue forecast, saying it does not expect further sales of its COVID-19 shot in the United States this year.
The company said it was late to the U.S. market and also pointed to softer demand in the face of a global vaccine supply glut.
So far 11,990 Novavax vaccine doses have been administered in the United States, according to latest government data.
The vaccine, which has already been cleared in countries such as Japan and Australia for use among adolescents, has also been plagued by manufacturing snags, regulatory delays and sluggish uptake in key markets such as Europe.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.